BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1725 related articles for article (PubMed ID: 31876895)

  • 21. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer: A protocol for systematic review and meta-analysis.
    Liu G; Lv X; Ding Y; Guo Y
    Medicine (Baltimore); 2021 Jun; 100(24):e26367. PubMed ID: 34128893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
    Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.
    Xu J; Zhao J; Wang J; Sun C; Zhu X
    Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.
    Sun L; Zhang L; Yu J; Zhang Y; Pang X; Ma C; Shen M; Ruan S; Wasan HS; Qiu S
    Sci Rep; 2020 Feb; 10(1):2083. PubMed ID: 32034198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
    Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
    Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.
    Chen Y; Han H; Cheng J; Cheng Q; Zhu S; Zhan P; Liu H; Song Y; Lv T
    Cancer Immunol Immunother; 2024 Jun; 73(8):155. PubMed ID: 38834888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
    Elias R; Giobbie-Hurder A; McCleary NJ; Ott P; Hodi FS; Rahma O
    J Immunother Cancer; 2018 Apr; 6(1):26. PubMed ID: 29618381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
    Man J; Millican J; Mulvey A; Gebski V; Hui R
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34084999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
    Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
    Front Immunol; 2021; 12():705096. PubMed ID: 34434192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
    Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
    Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
    Shen X; Zhao B
    BMJ; 2018 Sep; 362():k3529. PubMed ID: 30201790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
    JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 87.